(Yicai) June 8 -- Guangzhou Pharmaceutical Group has recently forged multiple collaborations in Central Asia, accelerating the Chinese pharmaceutical giant’s strategic expansion in areas such as pharmaceutical trade, cross-border supply chains, localized production and healthcare-related investments.

In terms of production, Baiyunshan Hanfang, a subsidiary of Guangzhou Pharma, is linking arms with Kazakhstan’s Kolon Pharma to produce anti-tumor active pharmaceutical ingredients, deepening collaboration in the upstream industry chain. While sister firm Baiyunshan Tianxin Pharmaceutical is teaming up with Uzbekistan’s ADN Pharm-Sanoat on drug registration, channel development and localized brand operations.

Guangzhou Pharma has also reached a preliminary agreement with Uzbekistan’s Omon Med Pharm to explore new models of joint factory construction and collaborative research and development.

Regarding capital synergy, Guangzhou Pharma has struck an agreement with Samruk-Kazyna, Kazakhstan’s sovereign wealth fund, to leverage the fund’s resource advantages in sectors such as energy, logistics and chemicals to deepen collaboration in pharmaceutical trade, industrial investment and localized operations.

While in the logistics and supply chain sector, Guangzhou Pharma is working with China-Uzbekistan Logistics, which operates bonded warehouses for Asia-Europe railway container transport and a well-established cold chain logistics system, in areas including cold chain transportation, bonded warehousing and cross-border distribution services.

Editor: Kim Taylor